Elizabeth Higgins, Ph.D.
Chief Technology Officer

Elizabeth "Liz" Higgins joined NysnoBio as VP, Head of CMC, and in Q3 2022 was promoted to Chief Technology Officer. She brings over 20 years of experience in clinical development, process and analytical development, QC and clinical manufacturing, and managing CROs and CDMOs. Prior to joining NysnoBio, Liz was head of CMC at Prevail Therapeutics, where she was responsible for external GMP manufacturing to support clinical trials of their AAV gene therapies as well as CMC sections for FDA and EMEA regulatory submissions. Before Prevail, she was part of the Tech Ops team at Voyager Therapeutics, responsible for analytical sciences, process analytics and quality control for Voyager’s AAV gene therapies.

Liz holds an MBA from Boston University, and a PhD in Molecular and Medical Genetics from the University of Toronto.